pharmaceuticals
Stay in step with market opportunities and get insights, actionable trade ideas and dedicated support.
Sort by:
- Newest
- Popular
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
Why trade with FOREX.com?
Choose from thousands of markets across forex, share CFDs, commodities, crypto, indices and more
Elevate your trades with industry-leading TradingView charts and exclusive Performance Analytics tools
Enjoy a seamless trading experience with personalised platform walkthroughs, clear guides and first-class support via phone, email or chat.
We're part of StoneX Group, a NASDAQ-listed financial giant with a 100-year track record and revenues exceeding $60 billion.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.